ESR1 and breast carcinoma: Overcoming resistance to endocrine therapies represents a pivotal challenge for enhancing treatment outcomes in women with estrogen receptor-alpha (ER) positive breast cancer, contributing to approximately half of all fatalities from the disease [1].